Form 8-K - Current report:
SEC Accession No. 0000950170-24-112904
Filing Date
2024-10-04
Accepted
2024-10-04 16:05:46
Documents
11
Period of Report
2024-10-03
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20241003.htm   iXBRL 8-K 57144
  Complete submission text file 0000950170-24-112904.txt   170894

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20241003.xsd EX-101.SCH 24862
13 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20241003_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 241354951
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)